Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.13USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$2.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,052,048
52-wk High
$5.59
52-wk Low
$0.78

Select another date:

Thu, Aug 10 2017

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.18

* Aeterna Zentaris reports second quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris engages advisors and provides update to shareholders

* Aeterna Zentaris engages advisors and provides update to shareholders

BRIEF-David Dodd responds to claim filed by Aeterna Zentaris

* David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore​

BRIEF-Aeterna Zentaris files claim against former CEO, former general counsel

* Aeterna Zentaris commences legal action against David Dodd and Philip Theodore

BRIEF-Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​

* Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO

BRIEF-NDA for Aeterna Zentaris' Macrilen granted PDUFA date

* NDA for Macrilen for the evaluation of growth hormone deficiency in adults granted December 30, 2017 PDUFA date

BRIEF-Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults

* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults

BRIEF-Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint

* Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint

BRIEF-Aeterna Zentaris intends to file NDA with respect to Macrilen in Q3

* Aeterna Zentaris intends to file NDA with respect to Macrilen™ in third quarter of 2017 Source text for Eikon: Further company coverage:

Select another date: